Rue Auguste Piccard 48
About UnivercellsUnivercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company’s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches.
Founders: Hugues Bultot and José Castillo
Founder and CEO: Hugues Bultot
Founder and CTO: José Castillo
Please click here for Univercells.
Tweets by Univercells
5 articles with Univercells
ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine
Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
7/16/2018Univercells SA (‘Univercells’) and Global Health Investment Fund (‘GHIF’) are pleased to announce the closing of a €16 million ($18.8 million) Series B equity financing. Investment proceeds will support the continued development of Univercells’ game-changing biomanufacturing technology, which has...
This funding will enable the company to launch a program aimed at developing its innovative protein platform, paving the way for the cost-effective production of biosimilars.
The proceeds will support the commercial roll-out of its viral platform and the completion of its recombinant platform.